Niagen Bioscience (NAGE) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
29 Apr, 2026Executive summary
Annual meeting scheduled for June 24, 2026, at 3:00 pm PT in Los Angeles, CA.
Shareholders will vote on director elections, auditor ratification, and executive compensation.
Proxy materials and annual report are available online, with options for electronic or paper delivery.
Voting matters and shareholder proposals
Election of eight directors is up for shareholder vote, with board recommending approval.
Ratification of Crowe LLP as independent auditor for fiscal year ending December 31, 2026.
Advisory vote on executive compensation as recommended by the Compensation Committee and approved by the board.
Board of directors and corporate governance
Board recommends voting for all eight nominated directors.
Director nominees include Frank Jaksch, Jr., Robert Fried, Steven Rubin, Wendy Yu, Gary Ng, Kristin Patrick, Ann Cohen, and Hamed Shahbazi.
Latest events from Niagen Bioscience
- Q1 2026 net sales rose 3% to $31.5M, net income $6.3M, $4.8M segment sale gain, $66.5M cash.NAGE
Q1 20266 May 2026 - Board recommends approval of all proposals, emphasizing governance and performance-linked pay.NAGE
Proxy filing29 Apr 2026 - Double-digit growth, strong margins, and clinical validation drive expansion in NAD+ wellness.NAGE
corporate presentation4 Mar 2026 - Net sales rose 30% and net income more than doubled in 2025, with strong outlook for 2026.NAGE
Q4 20254 Mar 2026 - Patented NAD+ solutions drive profitable growth, clinical trials, and new product innovation.NAGE
17th Annual LD Micro Main Event Conference3 Feb 2026 - Q2 2024 sales up 12% to $22.7M, breakeven net loss, and strong cash position.NAGE
Q2 20242 Feb 2026 - Strong IP, clinical progress, and new verticals position for growth in NAD-related markets.NAGE
Renmark’s Virtual Non-Deal Roadshow Series22 Jan 2026 - Niagen Plus IV launches in major US cities, with rapid expansion and Q3 revenue expected.NAGE
Lytham Partners Fall 2024 Investor Conference20 Jan 2026 - Record Q3 sales, 31% growth, and Niagen+ launch drive strong outlook and profitability.NAGE
Q3 202417 Jan 2026